Publications by authors named "Ann D Kwong"

Claim this Profile
S
SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.
Katyna Borroto-Esoda, David Wilfret, Xiao Tong, Andrew Plummer, Brian Kearney, Ann D Kwong

Microbiol Spectr· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of antiviral activity of SARS-CoV-2 M inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
Xiao Tong, Walter Keung, Lee D Arnold, Laura J Stevens, Andrea J Pruijssers, Ann D Kwong

Antimicrob Agents Chemother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating antiviral drug discovery: lessons from COVID-19.
Annette von Delft, Matthew D Hall, Ann D Kwong, Lisa A Purcell, Kumar Singh Saikatendu

Nat Rev Drug Discov· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
Xiao Tong, Jeanon Smith, Natalya Bukreyeva, Takaaki Koma, John T Manning, Ann D Kwong

Antiviral Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Randal A Byrn, Steven M Jones, Hamilton B Bennett, Chris Bral, Michael P Clark, Ann D Kwong

Antimicrob Agents Chemother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonstructural protein 5A (NS5A) and human replication protein A increase the processivity of hepatitis C virus NS5B polymerase activity in vitro.
Nagraj Mani, Alexander Yuzhakov, Olga Yuzhakov, Joyce T Coll, Jim Black, Ann D Kwong

J Virol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir-based treatment effects on hepatitis C virus in liver and blood.
Andrew H Talal, Rositsa B Dimova, Eileen Z Zhang, Min Jiang, Marina S Penney, Ann D Kwong

Hepatology· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
Xiao Tong, Ann D Kwong

Clin Infect Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HCV Revolution Did Not Happen Overnight.
Ann D Kwong

ACS Med Chem Lett· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Gururaj Kalkeri, Chao Lin, Jenna Gopilan, Kevin Sloan, Rene Rijnbrand, Ann D Kwong

Antimicrob Agents Chemother· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann M Tigges, Jennifer L Dorrian, Ann D Kwong

J Virol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann D Kwong

PLoS One· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.
James C Sullivan, Eileen Z Zhang, Doug J Bartels, Ann Tigges, Jennifer L Dorrian, Ann D Kwong

Virol J· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
Christian M Lange, Simone Susser, Eva Herrmann, Ursula Karey, Tara L Kieffer, Ann D Kwong

Scand J Gastroenterol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Ann D Kwong, Robert S Kauffman, Patricia Hurter, Peter Mueller

Nat Biotechnol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Ann D Kwong, Isabel Najera, Jill Bechtel, Scott Bowden, Joseph Fitzgibbon

Gastroenterology· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.
Bambang S Adiwijaya, Eva Herrmann, Brian Hare, Tara Kieffer, Chao Lin, Ann D Kwong

PLoS Comput Biol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).
Tara L Kieffer, Ann D Kwong, Gaston R Picchio

J Antimicrob Chemother· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
Ann D Kwong, Lindsay McNair, Ira Jacobson, Shelley George

Curr Opin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Doug J Bartels, Yi Zhou, Eileen Z Zhang, Michelle Marcial, Randal A Byrn, Ann D Kwong

J Infect Dis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Yi Zhou, Doug J Bartels, Brian L Hanzelka, Ute Müh, Yunyi Wei, Ann D Kwong

Antimicrob Agents Chemother· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Tara L Kieffer, Christoph Sarrazin, Janice S Miller, Martin W Welker, Nicole Forestier, Ann D Kwong

Hepatology· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
Yi Zhou, Ute Müh, Brian L Hanzelka, Doug J Bartels, Yunyi Wei, Ann D Kwong

J Biol Chem· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Christoph Sarrazin, Tara L Kieffer, Doug Bartels, Brian Hanzelka, Ute Müh, Ann D Kwong

Gastroenterology· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
Kai Lin, Robert B Perni, Ann D Kwong, Chao Lin

Antimicrob Agents Chemother· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis